Compare NGNE & IPI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NGNE | IPI |
|---|---|---|
| Founded | 2003 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Mining & Quarrying of Nonmetallic Minerals (No Fuels) |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 498.2M | 499.4M |
| IPO Year | 2014 | 2007 |
| Metric | NGNE | IPI |
|---|---|---|
| Price | $35.40 | $33.46 |
| Analyst Decision | Strong Buy | Strong Sell |
| Analyst Count | 7 | 1 |
| Target Price | ★ $63.57 | $25.00 |
| AVG Volume (30 Days) | 219.9K | ★ 250.4K |
| Earning Date | 05-08-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 0.93 | ★ 105.14 |
| EPS | N/A | ★ 0.56 |
| Revenue | N/A | ★ $298,328,000.00 |
| Revenue This Year | N/A | $5.01 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $59.84 |
| Revenue Growth | N/A | ★ 17.13 |
| 52 Week Low | $15.93 | $22.55 |
| 52 Week High | $37.27 | $50.34 |
| Indicator | NGNE | IPI |
|---|---|---|
| Relative Strength Index (RSI) | 68.81 | 40.66 |
| Support Level | $19.27 | $33.33 |
| Resistance Level | $36.37 | $35.78 |
| Average True Range (ATR) | 2.05 | 1.40 |
| MACD | 0.39 | 0.05 |
| Stochastic Oscillator | 95.22 | 26.68 |
Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACT(Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.
Intrepid Potash Inc produces and sells potash and potash byproducts in three main product segments: Potash, Trio, and Oilfield Solutions. The Potash segment produces and sells potash to the agricultural industry as a fertilizer input, the industrial market as a component of oil and gas drilling fluid, and the animal feed market as a nutrient supplement. The Trio segment produces and sells specialty fertilizer that consists of potassium, sulfate, and magnesium and is mined from langbeinite ore. The oilfield solutions segment offers water, high-speed potassium chloride mixing services, saltwater disposal services, and trucking services. The vast majority of revenue is generated in the United States, where the firm's production facilities are located.